Stock Taper Revenue: Increased by over 7% to $1.36 billion compared to $1.27 billion in Q3 2024.
Adjusted EBITDA: Rose over 7% to $111.7 million from $103.9 million.
Earnings Per Share (EPS): Increased by over 21% to $0.23 from $0.19 in the same quarter last year.
Inpatient Rehab Division: Revenue grew 16% to $328.6 million; adjusted EBITDA up 13% to $68 million.
Outpatient Rehab Division: Revenue increased 4% to $325.4 million; adjusted EBITDA decreased over 14% to $24.2 million.
Critical Illness Recovery Hospitals: Revenue rose over 4% to $609.9 million; adjusted EBITDA increased over 10% to $56.1 million.
Debt: $1.8 billion outstanding with a net leverage of 3.4x; cash on hand was $60.1 million.
Regulatory Update: CMS deferred the implementation of the 20% transmittal rule, resulting in a favorable revenue adjustment of $12 million to $15 million in EBITDA for the quarter.
Development Initiatives: Acquired a 30-bed critical illness recovery hospital in Memphis and added 3 outpatient clinics. Plans to add 395 inpatient rehabilitation beds by 2027.
Shareholder Returns: A cash dividend of $0.0625 per share was approved, reflecting commitment to shareholder value.
2025 Guidance: Revenue expected in the range of $5.3 billion to $5.5 billion; adjusted EBITDA forecasted between $510 million and $530 million. EPS guidance increased to $1.14 to $1.24.
2026 Outlook: Anticipated modest increases in Medicare reimbursement rates and continued development in inpatient rehab hospitals.
Outpatient Rehab Segment: Experienced softness due to reduced Medicare reimbursement rates and unfavorable payer mix, resulting in a decline in adjusted EBITDA margin from 9.1% to 7.4%.
High-Cost Outlier Impact: The increasing fixed loss threshold for high-cost outlier patients is a concern, limiting the ability to accommodate acutely ill patients and affecting admissions.
Regulatory Environment: Ongoing advocacy needed for Medicare policy reforms to support high-acuity patient treatment in long-term acute care hospitals.
Impact of 20% Transmittal Delay: Management indicated that the delay would lessen the anticipated headwinds for 2026 compared to previous expectations.
Payer Mix Issues: The outpatient segment faced challenges due to shifts in payer mix and geographic performance, which could affect margins.
Labor Costs: Labor environment appears more stable, with agency utilization back to pre-COVID levels and full-time labor costs increasing modestly.
Future Development Strategy: Plans to expand partnerships with larger health systems and consider larger rehab facilities in response to market demand. This summary encapsulates the key points from the earnings call, providing a balanced view of Select Medical's performance, strategic direction, and challenges faced in Q3 2025.
SOURCE: Q3 2025 EARNINGS CALL TRANSCRIPT